<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68784">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01860040</url>
  </required_header>
  <id_info>
    <org_study_id>13-04</org_study_id>
    <nct_id>NCT01860040</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemo for NSCLC</brief_title>
  <official_title>Neoadjuvant Chemotherapy for Non-metastatic Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Regional Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Regional Medical Center</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the rate of pathologic complete responses (pCR) at the time of definitive
      surgical resection of non-small cell lung cancer (NSCLC)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Rate of pathologic complete responses (pCR) at the time of definitive surgical resection of non-small cell lung cancer</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determine the rate of pathologic complete responses (pCR) at the time of definitive surgical resection of non-small cell lung cancer (NSCLC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histologic response rate and correlation with disease-free survival (DFS) and overall survival (OS)</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the histologic response rate and its correlation with DFS and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Imaging response rate and correlation with DFS and OS</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assess the CT and/or PET response rate and their respective correlations with DFS and OS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Non-squamous Cell Non-Metastatic Non-Small Cell Lung Cancer</condition>
  <condition>Squamous Cell Non-Metastatic Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cisplatin and pemetrexed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Cisplatin and pemetrexed</arm_group_label>
    <arm_group_label>Cisplatin and gemcitabine</arm_group_label>
    <other_name>Platinol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Cisplatin and pemetrexed</arm_group_label>
    <other_name>Alimta®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Cisplatin and gemcitabine</arm_group_label>
    <other_name>Gemzar®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients ≥ 18 years of age with either a mass suspicious for or histologically
             confirmed AJCC stage IB-IIIA NSCLC. For those without histologic confirmation of
             NSCLC, a biopsy will be done and only those patients with histologically confirmed
             NSCLC meeting all other eligibility criteria may proceed on protocol.

          2. Mass must be determined to be surgically resectable

          3. Eastern Cooperative Oncology Group (ECOG) performance status score &lt; 1 and a life
             expectancy &gt;3 months.

          4. Participants must have at least one evaluable lesion as defined by RECIST 1.1

          5. Absolute neutrophil count &gt; 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.5
             g/dL

          6. Serum creatinine ≤1.3 mg/dL (candidate for cisplatin chemotherapy), total bilirubin ≤
             2 mg/dL, AST/ALT ≤ 5 times the upper limit of normal range

          7. No prior chemotherapy or radiotherapy for NSCLC

          8. At least 5 years from diagnosis of another cancer except treated in-situ disease or
             surgically resected non-melanoma skin cancer with clear margins.

          9. Willingness to provide permission to biopsy NSCLC for collection of frozen
             pretreatment sample.

         10. Women of child-bearing potential (i.e., women who are pre-menopausal or not
             surgically sterile) must be willing to use an acceptable contraceptive method
             (abstinence, oral contraceptive or double barrier method) for the duration of the
             study and for 30 days following the last dose of study drug, and must have a negative
             urine or serum pregnancy test within 2 weeks prior to beginning treatment on this
             trial

        Exclusion Criteria:

          1. Active clinically serious infection &gt; CTCAE (version 4.03) Grade 2.

          2. Serious non-healing wound, ulcer, or bone fracture.

          3. Major contraindication to surgical resection of NSCLC

          4. Inability to complete informed consent process and adhere to the protocol treatment
             plan and follow-up requirements.

          5. Concurrent severe illness such as active infection, or psychiatric illness/social
             situations that would limit safety and compliance with study requirements.

          6. Patients receiving any other investigational agents.

          7. Pregnant or lactating females
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chari Poteet, RN</last_name>
    <phone>623-207-3000</phone>
    <email>clinicaltrials@ctca-hope.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>India Hill, CCRP</last_name>
    <phone>623-207-3000</phone>
    <email>clinicaltrials@ctca-hope.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Western Regional Medical Center</name>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <zip>85338</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Glen J Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>May 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Western Regional Medical Center</investigator_affiliation>
    <investigator_full_name>Glen Weiss</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
